Alnylam Shares Fall 2.66% on 44% Volume Drop to 129th Rank

On September 10, 2025, , , . , reflecting reduced liquidity and investor engagement following recent market dynamics.

Analysts noted that Alnylam’s performance was influenced by mixed signals from its pipeline updates and regulatory timelines. A key focus remained on the company’s progress with Givosiran, a therapy for , where recent data releases failed to meet heightened expectations. Investors appeared cautious, . Market participants also highlighted the absence of near-term catalysts, such as Phase 3 trial readouts or FDA advisory committee meetings, which typically drive volatility in biotech stocks.

Regarding the back-test methodology: The proposed framework ranks the top 500 U.S.-listed stocks by daily trading volume, equal-weights positions, and rebalances daily without transaction costs. . . Adjustments to parameters—such as weighting schemes, cost inclusion, or alternative benchmarks—would require explicit clarification before execution.